JPRN-jRCT2031230575尚未招募2 期
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors - HERTHENA-PanTumor01
Inoguchi Akihiro0 个研究点目标入组 120 人开始时间: 2024年1月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Sign and date the ICF, prior to the start of any study-specific qualification procedures. A separate tissue screening consent will be obtained from all subjects to meet the baseline tumor tissue requirement.
- •2. Is a male or female aged >=18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old).
- •3. Has locally advanced unresectable or metastatic disease (not curable by surgery or radiation) as follows:
- •3-1. Cutaneous or acral melanoma
- •a. Histologically or cytologically confirmed cutaneous or acral melanoma
- •b. Disease progression after having received >=1 prior line of anti-PD-1 or anti-PD-L1 based therapy. If the subject had BRAFm melanoma, they must have had disease progression on BRAF/MEK inhibitor therapy as well.
- •3-2. Squamous cell carcinomas of the head and neck
- •c. Squamous cell carcinoma of the head and neck that is human papillomavirus (HPV) positive or negative. Primary tumor site must have arisen initially from the oral cavity, oropharynx, hypopharynx, or larynx. Tumors arising from the nasopharynx are excluded.
- •d. Disease progression after having received treatment with a PBC regimen with or without anti-PD-1 therapy
- •3-3. Gastric or GEJ adenocarcinoma
- •e. Tumor tissue must be confirmed as negative for HER2 expression (immunohistochemistry [IHC] 0/1+ or IHC 2+/in situ hybridization negative) as classified by ASCO-CAP guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.
- •f. Disease progression after having received treatment with a previous PBC with or without anti-PD-1 therapy.
- •4. Has >=1 measurable lesion on CT or MRI as per RECIST v1.1 by investigator assessment.
- •5. Provides a pretreatment tumor tissue sample of sufficient quantity, as defined in the Study Laboratory Manual. The pretreatment tumor tissue can be provided as either
- •a. Tissue collected from a biopsy performed since progression while on or after treatment with the most recent cancer therapy regimen and prior to signing of the tissue ICF
- •b. Pretreatment tumor biopsy from >=1 lesion not previously irradiated and amenable to sampling
- •The pretreatment tissue requirement may be waived after discussion and agreement with the Sponsor.
- •6. Has Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at screening.
排除标准
- •1. Has HER2-positive gastric cancer as classified by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.
- •2. Has nasopharyngeal cancer.
- •3. Has mucosal or uveal melanoma.
- •4. Has any history of interstitial lung disease (ILD; including pulmonary fibrosis or radiation pneumonitis), has current ILD, or is suspected to have such disease by imaging during screening.
- •5. Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses.
- •6. Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to Cycle 1 Day 1. Subjects who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study.
- •7. Had prior treatment with an anti-HER3 antibody and/or ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan).
- •8. Has history of other active malignancy within 3 years prior to Cycle 1 Day 1, except the following:
- •a. Adequately treated nonmelanoma skin cancer
- •b. Adequately treated intraepithelial carcinoma of the cervix
- •c. Any other curatively treated in situ disease.
- •9. Has any evidence of severe or uncontrolled diseases (eg, active bleeding diatheses, active serious infection) psychiatric illness/social situations, geographical factors, substance abuse, or other factors that, in the investigator's opinion, make it high risk for the subject to participate in the study or that would jeopardize compliance with the protocol.
研究者
相似试验
招募中
1 期
Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumorsocally Advanced or Metastatic Solid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-507641-29-00Daiichi Sankyo Inc.120
招募中
2 期
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsOvarian CarcinomaEndometrial CancerEsophageal CancerPancreatic CarcinomaNon-small Cell Lung Cancer (NSCLC)Gastric CancerBreast CancerProstate CancerProstate CancerLung CancerCervical CancerHead and Neck CancerEsophageal CancerProstate CancerCervical CancerBladder CancerLung CancerBreast CancerMelanomaMelanomaHead and Neck CancerGastric CancerBladder CancerMelanomaHead and Neck CancerGastric CancerCervical CancerBladder CancerLung CancerBreast CancerEsophageal CancerNCT06172478Daiichi Sankyo740
招募中
1 期
Study of Biological Effect in Tumor Samples from Clinical Trial Patients Treated with Ds8201Patients diagnosed with advanced or metastatic cancer treated with Trastuzumab Deruxtecan in the context of a clinical trial/expanded access/ compassionate use or standard treatment, irrespective of histologic type.CTIS2023-508830-33-00Solti Group180
招募中
2 期
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 AlterationsSolid TumoursNCT06581432Boehringer Ingelheim588
招募中
2 期
ONO-4538 Phase II (Rollover) Study (ONO-4538-98)Pan-TumorJPRN-jRCT2080225345ONO PHARMACEUTICAL CO., LTD.59